How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,974 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Delays to anti-tuberculosis treatment intiation among cases on directly observed treatment short course in districts of southwestern Ethiopia: a cross sectional study. (PubMed)

Delays to anti-tuberculosis treatment intiation among cases on directly observed treatment short course in districts of southwestern Ethiopia: a cross sectional study. Delayed tuberculosis (TB) diagnosis and treatment increase morbidity, mortality, expenditure, and transmission in the community. This study assessed patient and provider related delays to diagnosis and treatment of TB.A cross-sectional study was conducted among 735 new adult TB cases registered between January to December 2015 (...) predictors of delays and statistical significance was judged at p < 0.05.The median (inter-quartile range) of patient, provider and total delays were 25 (IQR;15-36), 22 (IQR:9-48) and 55 (IQR:32-100) days, respectively. More than half (54.6%) of the total delay was attributed to health system. Prior self-treatment [adjusted Odds Ratio (aOR)]: 1.72, 95% confidence interval [CI]:1.07-2.75), HIV co-infection (aOR:1.8, 95% CI: 1.05-3.10) and extra-pulmonary TB (aOR: 1.54,95% CI:1.03-2.29) were independently

Full Text available with Trip Pro

2019 BMC Infectious Diseases

82. Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis. (PubMed)

Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis. Treatment of latent tuberculosis infection (LTBI) in high-risk groups is an effective strategy for TB control and elimination in low incidence settings. A nine-month course of daily isoniazid (INH) has been the longest prescribed therapy; however, completion rates are suboptimal. We need data to guide TB program outreach efforts (...) , 0.81), patients with diabetes (HR = 0.77, 95% CI: 0.60, 0.98), and patients with HIV (HR = 0.39, 95% CI: 0.30, 0.51) had a lower risk of treatment default. However, black patients (HR = 1.57, 95% CI: 1.44, 1.70), Hispanic patients (HR = 1.54, 95% CI: 1.43, 1.66), and non-U.S.-born persons living in the United States ≤5 years (HR = 1.25, 95% CI: 1.18, 1.32) were significantly more likely to default on therapy.In this analysis of INH treatment outcome, we see high levels of treatment discontinuation

Full Text available with Trip Pro

2019 BMC Public Health

83. TB/HIV co-infections and associated factors among patients on directly observed treatment short course in Northeastern Ethiopia: a 4 years retrospective study (PubMed)

TB/HIV co-infections and associated factors among patients on directly observed treatment short course in Northeastern Ethiopia: a 4 years retrospective study Human immunodeficiency virus (HIV) and tuberculosis (TB) are the leading independent global causes of death among patients with infectious diseases. Additionally, due to the shared immune defense mechanisms, they are the leading cause of co-morbidities globally. However, little information was found regarding the proportion of TB/HIV co (...) -infection in the study area. Thus, this study determined the proportion and associated factors of TB/HIV co-infection.All TB patients treated from January/2011 to December/2014 were included in this study. Data were collected from three health centers namely; Kobo, Robit and Gobiye. Data were entered, cleared, and analyzed using SPSS version 20. Frequency, percentage, median and range were used to present the data. To assess the associated factors, logistic regression was employed.Of the total 990 TB

Full Text available with Trip Pro

2015 BMC research notes

84. Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France

Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France (PARCOURS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02566148 Recruitment Status : Completed First Posted : October 2, 2015 Last Update Posted : May 15, 2017 Sponsor: French National Institute for Health

2015 Clinical Trials

85. Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy. (PubMed)

Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy. Systemic immune activation is a striking consequence of HIV-1 infection. Even in virologically suppressed patients, some hyperactivity of the immune system and even of the endothelium and of the coagulation pathway may persist. Apart from immune deficiency, this chronic activation may contribute to various morbidities including atherothrombosis, neurocognitive disorders, liver steatosis (...) and osteoporosis, which are currently main challenges. It is therefore of major importance to better understand the causes and the phenotypes of immune activation in the course of HIV-1 infection. In this review we will discuss the various causes of immune activation in HIV-1 infected organisms: the presence of the virus together with other microbes, eventually coming from the gut, CD4+ T cell lymphopenia, senescence and dysregulation of the immune system, and/or genetic factors. We will also describe

Full Text available with Trip Pro

2015 HIV medicine

86. A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses

A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail (...) Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

2015 Clinical Trials

87. A randomized clinical trial evaluating prophylactic single-dose vs prolonged course of antibiotics for caesarean section in a high HIV-prevalence setting. (PubMed)

A randomized clinical trial evaluating prophylactic single-dose vs prolonged course of antibiotics for caesarean section in a high HIV-prevalence setting. The evidence that perioperative antibiotics for caesarean delivery are effective in reducing infective morbidity is unequivocal. In developing countries, especially those with high HIV-prevalence, clinicians have increasingly become anxious about the efficacy of perioperative antibiotics, hence the adoption of treatment regimens, as described (...) in this study. We set out to investigate if these fears have a basis by conducting a randomised clinical trial. The setting was two tertiary units in a developing country with a significant HIV-prevalence. The outcome measures assessed were: pyrexia, wound infection, admission with puerperal sepsis, laparotomy for pelvic abscess and duration of hospital stay. There was no statistically significant difference between the two arms of the study with regard to the above outcomes. Our conclusion is that the two

2014 Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology Controlled trial quality: uncertain

88. BHIVA guidelines for the management of tuberculosis in adults living with HIV

as 1 or 2 as follows: • A GRADE 1 recommendation is a strong recommendation for (or against) a course of action, where the benefits clearly outweigh the risks (or vice versa) for most, if not all, PLWH. Most clinicians and HIV- positive individuals should and would want to follow a strong recommendation unless there is a clear BHIVA guidelines for the management of TB in adults living with HIV 8 rationale for an alternative approach. A strong recommendation usually starts with the standard wording (...) ). Continuation of TB prophylaxis after treatment of active TB is therefore not recommended in the UK setting, but ART should be continued. 6.5 Treatment of LTBI in individuals exposed to drug-resistant TB For HIV-positive individuals with a history of exposure to drug-resistant TB (resistant to one or more first-line drugs), there are limited data to support any particular course of action. To help management of such cases an individualised management plan might be formulated from collaboration between

2018 British HIV Association

89. HIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP)

, the DSMB recommended that all study participants should be offered study drug. A total of 23 participants became infected with HIV over the course of the study: three in the daily TDF-FTC group and 20 in the deferred (no-PrEP) group, representing a rate difference in HIV infection of 7.8 per 100 person-years (90% CI 4.3–11.3) The relative risk reduction was 86% (90% CI 64–96%) and the number needed to treat over 1 year to prevent one HIV infection was 13 (90% CI 9–23). BHIVA/BASHH guidelines on the use (...) followed up every 8 weeks for HIV testing and risk-reduction advice, and every 6 months for sexually transmitted infection (STI) testing for a total of 431 person-years of follow-up. Primary endpoint was HIV infection. At interim review, the placebo group was discontinued and all study participants were offered study drug. Over the course of the study, 16 people became infected with HIV: two in the TDF-FTC group and 14 in the placebo group, representing a relative risk reduction of 86% (95% CI 40–98

2018 British HIV Association

90. Biobehavioural survey guidelines for populations at risk for HIV

Biobehavioural survey guidelines for populations at risk for HIV Global HIV Strategic Information Working Group Biobehavioural Survey Guidelines For Populations At Risk For HIVAuthorship and acknowledgements Authors Abu Abdul-Quader, Mark Berry, Trista Bingham, Janet Burnett, Maxia Dong, Amy Drake, Avi Hakim, Wolfgang Hladik, Angele Marandet, Anne McIntyre, Chris Murrill, Joyce Neal and Nita Patel of the US Centers for Disease Control and Prevention (CDC); Rajatashuvra Adhikary (formerly of FHI (...) Mills of FHI 360; staff of the Joint United Nations Programme on HIV/AIDS (UNAIDS); Jesus Garcia Calleja of WHO; Thomas Rehle of the Human Sciences Research Council (HSRC); Tobi Saidel of PEMA Partners; and Ted Alcorn of the Bill & Melinda Gates Foundation. Reviewers Maxia Dong, Shahul Ebrahim, Avi Hakim, Wolfgang Hladik, Amy Herman-Roloff, Andrea Kim, Rachel Kwezi, Sheryl Lyss, John Macom, Chris Murrill, Patrick Nadol, Sanny Chen Northbrook, Bharat Parekh, Nita Patel, Dimitri Prybylski, Ray

2017 World Health Organisation HIV Guidelines

91. Individual support of nurses using electronic medicine monitors can improve HIV treatment

routine clinic visits. We did mixed-effects, intent-to-treat analyses to examine treatment effects on the primary outcome of log10 viral load collected at months 5, 10, and 15. The viral load results were exponentiated (with base 10) for easier interpretation. Using cohort data from 7347 Dutch patients with HIV to calculate the natural course of illness, we developed a lifetime Markov model to estimate the primary economic outcome of lifetime societal costs per quality-adjusted life-years (QALYs (...) Individual support of nurses using electronic medicine monitors can improve HIV treatment Individual support of nurses using electronic medicine monitors can improve HIV treatment Discover Portal Discover Portal Individual support of nurses using electronic medicine monitors can improve HIV treatment Published on 10 October 2017 doi: Use of electronic pill bottles that record when they are opened and follow-up discussion of the printed readouts with nurses improved HIV outcomes. It is thought

2019 NIHR Dissemination Centre

92. Antenatal screening approaches effective in preventing MTCT of HIV, HBV, syphilis and rubella in vulnerable populations

Antenatal screening approaches effective in preventing MTCT of HIV, HBV, syphilis and rubella in vulnerable populations TECHNICAL REPORT Antenatal screening approaches effective in preventing mother- child-transmission of HIV, hepatitis B, syphilis and rubella in vulnerable populations Literature review www.ecdc.europa.euECDC TECHNICAL REPORT Antenatal screening approaches effective in preventing mother-to-child transmission of HIV, hepatitis B, syphilis and rubella in vulnerable populations (...) Leino, Markku Kuusi, and Mika Salminen Helena de Carvalho Gomes and Ana-Belen Escriva are acknowledged for internal ECDC support. Suggested citation: European Centre for Disease Prevention and Control. Antenatal screening approaches effective in preventing mother-child-transmission of HIV, hepatitis B, syphilis and rubella in vulnerable populations. Stockholm: ECDC; 2017. Stockholm, March 2017 ISBN 978-92-9498-032-8 doi: 10.2900/580446 Catalogue number TQ-02-17-142-EN-N © European Centre for Disease

2017 European Centre for Disease Prevention and Control - Literature Reviews

93. Guidelines on the public health response to pretreatment HIV drug resistance

Guidelines on the public health response to pretreatment HIV drug resistance Introduction i GUIDELINES GUIDELINES ON THE PUBLIC HEALTH RESPONSE TO PRETREATMENT HIV DRUG RESISTANCE JULY 2017 HIV DRUG RESISTANCEGUIDELINES ON JULY 2017 THE PUBLIC HEALTH RESPONSE TO PRETREATMENT HIV DRUG RESISTANCEGuidelines on the public health response to pretreatment HIV drug resistance: July 201 7 ISBN 978-92-4-155005-5 © World Health Organization 2017 Some rights reserved. This work is available under (...) in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Guidelines on the public health response to pretreatment HIV drug resistance, July 201 7 . Geneva: World Health Organization; 201 7 . Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/ bookorders. To submit requests for commercial use and queries

2017 World Health Organisation HIV Guidelines

94. Consolidated guidelines on person-centred HIV patient monitoring and case surveillance

Consolidated guidelines on person-centred HIV patient monitoring and case surveillance CONSOLIDATED GUIDELINES ON PERSON-CENTRED HIV PATIENT MONITORING AND CASE SURVEILLANCE JUNE 2017 GUIDELINES HIV STRATEGIC INFORMATION FOR IMPACTCONSOLIDATED GUIDELINES ON PERSON-CENTRED HIV PATIENT MONITORING AND CASE SURVEILLANCE JUNE 2017Consolidated guidelines on person-centred HIV patient monitoring and case surveillance ISBN 978-92-4-151263-3 © World Health Organization 2017 Some rights reserved (...) the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Consolidated guidelines on person-centred HIV patient monitoring and case surveillance. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests

2017 World Health Organisation HIV Guidelines

95. Consolidated guideline on sexual and reproductive health and rights of women living with HIV

health and rights of women living with HIV 4 Table 1: Summary list of WHO recommendations for the sexual and reproductive health and rights (SRHR) of women living with HIV Note: Where recommendations apply to “key populations” this includes women living with HIV and therefore these have been included in these guidelines. A. Creating an enabling environment Recommendation (REC) Strength of recommendation, quality of evidence Healthy sexuality across the life course REC A.1: Adolescent-friendly health (...) ) Psychosocial support GPS A.1 (NEW): Psychosocial support interventions, such as support groups and peer support, provided by, with, and for women living with HIV, should be included in HIV care. Healthy sexuality across the life course GPS A.2 (NEW): Women living with HIV in all their diversity should be supported in their choice to have safe and fulfilling sexual relationships and sexual pleasure as they age. Women living with HIV who choose not to be sexually active should also be supported

2017 World Health Organisation Guidelines

96. Consolidated guideline on sexual and reproductive health and rights of women living with HIV

(Department of Reproductive Health and Research [RHR]), Rachel Baggaley (Department of HIV/ AIDS), John Beard (Department of Ageing and Life Course [ALC]), Ana Pilar Betrán Lazaga (Department of RHR), Francoise Bigirimana (WHO Regional Office for Africa), Sonja Caffe (WHO Regional Office for the Americas/Pan American Health Organization [PAHO]), Rebekah Bosco Thomas (Gender, Equity and Human Rights T eam), Nathalie Broutet (Department of RHR), T arun Dua (Department of Mental Health and Substance Abuse (...) of evidence Healthy sexuality across the life course REC A.1: Adolescent-friendly health services should be implemented in HIV services to ensure engagement and improved outcomes. 1 Strong recommendation, low- quality evidence Integration of SRHR and HIV services REC A.2: In generalized epidemic settings, antiretroviral therapy (ART) should be initiated and maintained in eligible pregnant and postpartum women and in infants at maternal and child health care settings, with linkage and referral to ongoing

2017 World Health Organisation Guidelines

97. British HIV Association guidelines for the management of HIV infection in pregnant women

4.2.2 HIV resistance testing should be performed before initiation of treatment (as per BHIVA guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012), except for late-presenting women. Post short-course treatment a further resistance test is recommended to ensure that mutations are not missed with reversion during the off-treatment period. Grading: 1D 4.2.3 In women either who conceive on highly active antiretroviral therapy (HAART) or who do not require HAART (...) additional baseline investigations com- pared with non-pregnant HIV-positive women other than those routinely performed in the general antenatal clinic. Grading: 1D 4.2.2 HIV resistance testing should be performed before initiation of treatment (as per BHIVA guidelines for the treatment of HIV-1 positive adults with anti- retroviral therapy 2012; www.bhiva.org/Publishedand Approved.aspx), except for late-presenting women. Post short-course treatment a further resistance test is rec- ommended to ensure

2012 The Children's HIV Association

98. A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults - Full (...) Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein

2018 Clinical Trials

99. A Phase 1/2a Study of PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults

A Phase 1/2a Study of PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults A Phase 1/2a Study of PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. A Phase 1/2a Study of PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier

2018 Clinical Trials

100. Fatal Disseminated Kaposi’s Sarcoma in Two Patients with Human Immunodeficiency Virus (HIV) Infection Fatal Disseminated Kaposi’s Sarcoma in Two Patients with Human Immunodeficiency Virus (HIV) Infection (PubMed)

and disseminated KS is presented in two patients with HIV/AIDS. CASE REPORT A 25-year-old man and a 30-year-old man with HIV/AIDS presented with KS affecting the skin, oral cavity, gastrointestinal tract, liver, lungs, kidneys, adrenal glands, and bone. Both patients had a rapidly deteriorating clinical course associated with a low CD4 count and developed respiratory failure and death. CONCLUSIONS Fatal disseminated KS is associated with severe immunosuppression due to with a low CD4 count. The presentation (...) of these two cases highlights the potentially aggressive clinical course of KS in patients with HIV/AIDS and reinforces the need for early diagnosis and rapid treatment with HAART.

Full Text available with Trip Pro

2018 The American journal of case reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>